Drug Profile

4D 710

Alternative Names: 4D 710

Latest Information Update: 17 Jan 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator 4D Molecular Therapeutics
Class Antifibrotics; Gene therapies
Mechanism of Action Gene transference

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

Yes - Cystic fibrosis
New Molecular Entity No

Highest Development Phases

Phase I/II Cystic fibrosis

Most Recent Events

17 Jan 2025 Molecular Therapeutics plans pivotal trial proposal for Cystic fibrosis mid-2025
07 Jun 2024 Updated efficacy, adverse event and pharmacodynamic data from a phase I/II AEROW trial in Cystic fibrosis released by 4D Molecular Therapeutics
28 Mar 2024 4D 710 receives Orphan Drug status for Cystic fibrosis in USA

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com